Spinocerebellar Ataxia Biosample Access
Investigators interested in obtaining Spinocerebellar Ataxia (SCA) biospecimens should submit their application through the NINDS biosample online submission webform, which also details the application requirements. Requests are reviewed by the Spinocerebellar Ataxia Biospecimen Resource Access Committee (SCA-BRAC), an external scientific review panel, to ensure that these biosamples are appropriately disseminated for SCA biomarker discovery, assay optimization and replication studies.
Step 1: Determine Sample Availability
Biospecimens and associated data are available from the following SCA cohorts:
- READISCA: a longitudinal observational study for premanifest and early manifest carriers of SCA1 or SCA3 mutations.
- CRC-SCA: a longitudinal observational history study supported by the National Ataxia Foundation (NAF) for patients with a confirmed diagnosis of SCA 1, 2, 3, 6, 7, 8, or 10. Note: While participants enrolled in CRC-SCA are followed longitudinally, the biospecimen collection is performed cross-sectionally.
- Data and biospecimens available;
- Material Transfer Agreements and Data Use Agreements required for each collection;
- Any tissue processing or other fees associated with the biospecimens and tissue.
Step 2: Submit Online Application
All applications are submitted through an online webform. Within the webform, applicants are required to upload the following files (in pdf, gif, jpg, jpeg, or png file formats):
- Research Strategy(pdf, 40 KB) (pdf, 40 kb) - (4 page limit)
- Biosample template(pdf, 181 KB) (pdf, 180 kb) - (This should include information on sample availability)
The first page of the webform requires the investigator to fill in basic information (e.g name, institution, address) and to upload the biosketch. The second page of the webform requires the investigator to upload the application files (e.g. Research Strategy and Table Summary) and provide information about funding support for the study.
Applications for biospecimen access will be received on a rolling basis and reviewed according to the following cycle
|Date Submitted||Reviewed by|
|September 18, 2021 - December 17, 2021||January 31, 2022|
|December 18, 2021 - February 18, 2022||March 17, 2022|
|February 19, 2022 - April 15, 2022||May 19, 2022|
|April 16, 2022 - June 17, 2022||July 14, 2022|
|June 18, 2022 - August 19, 2022||September 15, 2022|
|August 20, 2022 - October 21, 2022||November 17, 2022|
|October 22, 2022 - December 16, 2022||January 19, 2023|
Please note that your application will be shared with Program Staff from NINDS as well as BioSEND at Indiana University. The SCA-BRAC subscribes to the ethical requirements, as described within Confidentiality Agreement(pdf, 351 KB) (pdf, 350 kb).
Step 3: SCA BRAC Reviews Application
The BRAC committee will assess the applications based on experimental rationale, feasibility/reproducibility of the assays, expertise of the investigator, availability of the institutional resources to support the study, and the statistical analysis of the number of samples required for the hypothesis testing. Investigators will be notified by email regarding the outcome of the review (i.e. approve, approve upon revisions, or deny), ususally within a week after the review meeting. Summary statements are released 2-3 weeks after review. For applications that were ‘approved upon revisions’, investigators will be notified about concerns that need to be addressed before the application can move forward. Please note that the SCA BRAC does not provide funding.
If sample access is approved by the SCA BRAC, the two possible outcomes are:
- If the study has funding, the samples are distributed to the investigator following a virtual meeting to introduce the sample distribution process (“on-boarding”) and after fulfilment by the investigator of additional requirements specified by BioSEND (i.e. MTA, Data Use Agreement, data analysis and sharing plan). For questions, please contact Christine Swanson-Fischer, Ph.D.
- If the investigator has yet to obtain funding for the study, the BRAC will issue a letter to the applicant documenting provisional access to the samples requested. This letter can be used to support an application for funding opportunities from the NIH or other organizations. Conditional approvals will be valid for a period of up to 12 months.
Questions regarding the review process should be directed to the NINDS BRAC Coordinator, Christine Swanson-Fischer, PhD.
View the current list of approved Biospecimen Requests(pdf, 91 KB) (pdf, 91 kb) through the SCA BRAC.
View the complete SCA BRAC roster(pdf, 14 KB) (pdf, 14 kb)